Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proposed EU HTA Methods Pose Challenges For Cancer Therapies, Warns EFPIA

Executive Summary

Proposed methods for conducting EU-level joint clinical assessments could result in such a broad range of comparator therapies that companies are unable to fulfill scoping requirements, according to a report commissioned by industry federation EFPIA.

You may also be interested in...



‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.

Pharma Dubs EU HTA Proposal ‘Unworkable,’ But Patient Groups Support The Plan

Pharmaceutical companies, NGOs, and patient organizations were among the 129 respondents to the European Commission’s consultation on its draft implementing act for joint clinical assessments – but opinions on the proposal were divided.

New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies

New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS150047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel